Research
Breast cancer, Microenvironment et Immunotargeting : E. Liaudet-Coopman

RESEARCH TOPICS

The team’s projects focuses on triple-negative breast cancer (TNBC) for which effective treatments are crucially needed. In our integrated and multidisciplinary research, we want (i) to determine how the TNBC microenvironment is affected by proteases and the released bioactive fragments using N-TAILS proteomics (basic research axis); (ii) to target these extracellular/membrane proteins with proprietary antibodies as monotherapy, antibody-drug conjugates or combinations (translational axis); and (iii) to select TNBC subgroups for targeted and/or combined treatment with our proprietary antibodies (pre-clinical axis). Our ultimate objective is to translate our discoveries into clinical applications for the management of patients with specific TNBC subtypes in a personalized medicine approach. 

                                                    More

MAIN PUBLICATIONS

Alcaraz L, Mallavialle A, David T, Derocq D, Delolme F, Dieryckx C, Mollevi C, Boissière-Michot F, Huesgen P, Overall C, Tartare-Deckert S, Jacot W, Chardès T, Guiu S, Roger P, Reinheckel T, Moali C, Liaudet-Coopman E A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. Theranostics. 2021;11(13):6173-6192. doi:10.7150/thno.58254

Mansouri H, Alcaraz L, Mollevi C, Mallavialle A, Jacot W, Boissière-Michot F, Simony-Lafontaine J, Laurent-Matha V, Roger P, Liaudet-Coopman E, Guiu S Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. Cancers (Basel). 2020;12(5). doi:10.3390/cancers12051244

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo P-E, Azria D, Pèlegrin A, Larbouret C, Chardès T An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Int J Cancer. 2019;145(7):1838-1851. doi:10.1002/ijc.32273

Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy P-J, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Br. J. Cancer. 2018;119(1):76-79. doi:10.1038/s41416-018-0142-6


Team

Team Leader :
Emmanuelle Liaudet-Coopman

 

Institut de Recherche en
Cancérologie de Montpellier
Campus Val d’Aurelle

34298 Montpellier cedex 5

Tél. 33 (0)4 67 61 24 23
Fax 33 (0)4 67 61 37 87
emmanuelle.liaudet-coopman@inserm.fr

Discover the team


   

 

partners / funding

   


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés